Almanac A1C

Unraveling the Neurometabolic Architecture of Obesity: From Monogenic Syndromes to Polygenic Vulnerability and Hormonal Dysregulation

Posted

by

dr. Karunia Valeriani Japar

Table of Contents
Keywords: , , , ,

Introduction

The global rise in obesity and metabolic disease has prompted urgent re-examination of the underlying causes of fat accumulation. For decades, the prevailing view catered on the “calories in, calories out” model, which frames body weight as a simple balance between dietary intake and energy expenditure. However, a growing body of scientific evidence challenges this notion, demonstrating that fat regulation is a far more complex, biologically orchestrated process.

Recent advances in genetics, endocrinology, and neurobiology reveal that our bodies possess intricate mechanisms governing how energy is stored or burned, with hormones and genetic pathways playing decisive roles. Among these, insulin emerges as a central regulator of fat storage, tightly linked to hormonal signals and genetic variations influencing appetite, satiety, and metabolic partitioning.

Understanding the interplay between genetics, hormones and insulin is critical for moving beyond outdated calorie based paradigms. By illuminating the molecular roots of fat gain, we can dispel stigma, refocus prevention strategies, and develop more effective interventions for metabolic health. This article explores the real drivers of fat accumulation, genetics, key hormonal pathways and insulin, providing a foundation for evidence based approaches to obesity and metabolic disease prevention.

Overview Of Fat Regulation: Genetics And Hormones

Fat storage and distribution are fundamentally regulated by the intricate interplay between genetic determinants and hormonal signalling pathways. This relationship becomes strikingly apparent when examining rare genetic forms of obesity, which reveal that fat accumulation is not merely a matter of “calories in, calories out” but rather a complex process governed by hormonal control, particularly insulin, acting on genetically programmed metabolic pathways. Understanding these mechanisms is essential for comprehending both monogenic and polygenic forms of obesity and their metabolic consequences [1,2] .

Genetic Architecture of Fat Regulation

The genetic basis of fat regulation encompasses numerous genes that influence adipocyte development, function, and metabolic capacity. Genome-wide association studies have identified at least 58 genetic loci associated with body fat distribution, particularly waist to hip ratio, implicating adipose specific pathways in regional fat accumulation. These genetic variants mediate their effects through alterations in adipocyte morphology, specifically cell size and number, as well as through functional changes in lipolysis and lipogenesis [3].

  • Monogenic Obesity: Insights From Rare Genetic Disorder. Perhaps the most illuminating evidence for the genetic control of fat storage comes from monogenic obesity syndromes, where mutations in single genes cause severe early onset obesity despite normal or even controlled calorie intake. These rare conditions provide a “window into the true drivers of fat accumulation” and underscore that hormonal dysregulation, rather than overeating per se, determines whether energy is stores as fat or burned for fuel. Three key genetic defects within the hypothalamic leptin melanocortin pathways, leptin deficiency, proopiomelanocortin (POMC) deficiency, and melanocortin-4-receptor (MC4R) mutations, demonstrate the principle most clearly [2].
  • Leptin Deficiency. Congenital leptin deficiency is a rare autosomal recessive disorder caused by mutations in leptin (LEP) gene, most commonly observed in consanguineous families. Affected individuals typically have normal birth weight gain within the first few months of life, developing severe early onset obesity characterized by intense hyperphagia, impaired satiety, and constant food seeking behaviour. The clinical phenotype extends beyond obesity to include hyperinsulinemia, severe insulin resistance, hepatic steatosis, dyslipidemia, hypogonadotropic hypogonadism, and in some cases, recurrent severe bacterial infections that can be fatal in early childhood. At the molecular level, leptin mutations result in either truncated leptin synthesis or secretory defects, leading to undetectable circulating leptin levels. Remarkably, when treated with recombinant human leptin via daily subcutaneous injections, patients experience dramatic weight loss, reduction in body fat mass, and normalization of metabolic, hormonal, and immunological abnormalities. This therapeutic success demonstrates that leptin deficiency causes obesity not by increasing calorie intake alone but by fundamentally altering how the body partitions and stores energy [4,5].
  • POMC Deficiency. Mutations in the proopiomelanocortin (POMC) gene impair the synthesis or processing of POMC-derived peptides, particularly alpha-melanocyte-stimulating hormone (a-MSH), a critical satiety signal. POMC deficiency manifest as early onset severe obesity with hyperphagia, hypopigmentation ( due to reduced melanocortin signalling in skin), and endocrine abnormalities including adrenal insufficiency and secondary hypothyroidism. The obesity phenotype results from the failure of proconvertase 2 (PC2) to cleave POMC into a-MSH and related melanocortin peptides that normally activate melanocortin receptors in the hypothalamus. Studies in POMC knockout mice demonstrate that even when calorie intake is controlled, these animals become severely obese and hyperphagic, with reduced resting oxygen consumption and decreased thyroid hormone levels. Importantly, POMC-deficient mice show dramatically increased expression of MCH, an orexigenic neuropeptide, in the lateral hypothalamus, further driving energy conservation and fat storage. The critical findings is that POMC deficiency causes obesity by reprogramming the entire body to “hoard calories as fat” even when food consumption is strictly controlled, demonstrating that energy intake and energy storage can be completely dissociated [6,7,8,9].
  • MC4R Mutations. Melanocortin-4 receptor (MC4R) gene mutations represent the most common cause monogenic obesity in humans, accounting for 2-5% of severe early onset obesity cases, with over 150 pathogenic variants identified. MC4R is a G-protein coupled receptor expressed predominantly in the paraventricular nucleus (PVN) of the hypothalamus, where it integrates agonist signals from a-MSH (produced by POMC neurons) and antagonist signals from agouti related protein (AgRP). Loss of function MC4R mutations cause severe early onset obesity characterized by hyperphagia, increased linear growth, severe hyperinsulinemia and increased lean body mass. The inheritance pattern can either dominant or recessive, with recessive forms manifesting more severe phenotypes. Recent evidence demonstrate that MC4R signals through multiple pathways including Gas/cAMP, Gaq/11/phospholipase C, and b-arrestin recruitment, with Gaq/11 signalling being particularly important for the regulation of food intake and body weight. Notably, a specific MC4R mutation (F51L) that selectively impairs Gaq/11 signalling while preserving Gas signalling produces obesity, hyperphagia, and increased linear growth in mice, demonstrating that different signalling arms of MC4R contribute distinctly to energy balance regulation. The variable expressivity and incomplete penetrance of obesity in MC4R mutations carriers, where genetically identical mutations can produce different degrees of obesity across families, suggests that modifier genes and environmental factors interact with MC4R defects to determine final phenotype [10,11,12].
  • The Common Endpoint: Hyperinsulinemia. Critically, all three monogenic obesity conditions, leptin deficiency, POMC deficiency, and MC4R mutations, converge on a common metabolic endpoint. Chronic hyperinsulinemia (persistently elevated insulin levels). Whether leptin is missing, POMC signals are silenced, or MC4R is defective, insulin levels surge as the body shifts into “extreme conservation mode,” prioritizing fat storage over fat oxidation. This demonstrates that obesity in these genetic disorders is not simply a consequence of overeating but rather results from disrupted hormonal signalling that fundamentally alters energy partitioning the process by which the body decides whether incoming calories are stored as fat or burned for energy [13,14,15].
  • Polygenic Obesity Genes. Beyond monogenic syndromes, common polygenic obesity involves numerous genes with smaller individual effects. The fat mass and obesity associated  (FTO) gene on chromosome 16q12.2 represents the most common genetic risk locus for polygenic obesity, with variants strongly associated with increased body mass index and adiposity across diverse populations. FTO functions as an RNA N6-methyladenosine (m6A) demethylase that influences adipocyte differentiation by modulating expression of adipogenic transcription factors and controlling mitotic clonal expansion. FTO also influences leptin and ghrelin expression, thereby affecting appetite regulation [16,17].
  • Peroxisome Proliferator-Activated Receptor Gamma (PPARc) encodes the master transcriptional regulator of adipogenesis, without which adipocyte differentiation cannot occur. PPARc is essential for adipocyte survival, lipid storage, glucose metabolism and insulin sensitivity. Upon ligand binding, PPARc forms heterodimers with retinoid X receptor (RXR) and activates the transcription of lipogenic genes including fatty acid binding protein 4 (FABP4), CD36, adiponectin, and fatty acid synthase.

Studies in the GENetics of Adipocyte Lipolysis (GENiAL) cohort have identified specific genes such as ZNF436,NUP85, STX17, NID2, GGA3, and GRB2 as intrinsic regulators of lipolysis in adipocytes, demonstrating that genetic variants influence fat storage by modulating the balance between triglyceride synthesis and hydrolysis. These findings underscore the polygenic nature of fat regulation, wherein multiple individual effects collectively determine adipose tissue phenotype and metabolic function.

Hormonal Control of Fat Storage

Fat storage in the body is directed by several hormones that turn energy from food into body fat or release it when fuel is needed [2]

  • Leptin is a hormone release by fat cells once the body has enough fat. It signals the brain to reduce hunger and increase energy use. In rare cases, if leptin is missing or not working, the brain never gets the “full” signal, driving unstoppable hunger and rapid fat gain. in obesity, although leptin levels are high, the body can become “leptin resistant,” so this signal is ignored.
  • Adiponectin is another hormone from fat cells, but its levels drop when body fat rises. Adiponectin helps the body use sugar efficiently and burn fat for energy. High adiponectin means better metabolic health, but low levels contribute to insulin resistance.
  • Insulin is the main “ storage” hormone. After you eat carbohydrates, insulin rises. Its job in fat tissue is twofold:
    • It packs away fat by turning sugar and fatty acids into triglycerides for long term storage
    • It locks the fat away, preventing fat cells from breaking it down and releasing it for fuel.
  • Cathecholamines (like adrenaline) and growth hormone trigger the opposite effect, they promote the breakdown of stored fat, especially during fasting or exercise.
  • **Cortisol (**the stress hormone) can also promote fat storage, particularly in the belly, by stimulating fat cell growth under chronic stress
  • Thyroid hormones help regulate the rate at which the body burns energy, with low levels often leading to easier fat gain.

The Central Role of Insulin [18,19,20]

Insulin is “the gatekeeper”  of fat storage:

  • After a meal, especially one rich in sugar or starch, insulin rises.
  • Insulin instruct fat cells to pull in extra sugar and fat from the blood and store it as body fat
  • At the same time, insulin stops fat cells from releasing stored fat, even if the body needs energy. This effect is so strong that fat cells cannot shrink unless insulin first drops
  • Chronic high insulin (as seen in insulin resistance or type 2 diabetes) result in ongoing fat storage and blocks fat release, making weight loss very difficult.

Fat gain is not just about eating too much, it’s about how hormones, especially insulin, decide where the calories go. If insulin stays high, the body is primed to store fat and keep it locked away. Other hormones like leptin, adiponectin, and cortisol also influence this process, but insulin is the key signal that turns “ energy excess” into persistent body fat, even when calories are normal.

The Hypothalamic POMC Pathway

The hypothalamic proopiomelanocortin (POMC) pathway represents one of the most critical neuroendocrine systems governing energy balance, appetite regulation, and metabolic homeostasis. Located within the arcuate nucleus (ARC) of the hypothalamus, a brain region strategically positioned adjacent to the median eminence where the blood-brain barrier is fenestrated, POMC neurons serve as key integrators of peripheral metabolic signals and central neural inputs. This anatomical location allows POMC neurons to sense circulating hormones such as leptin, insulin, and ghrelin, and to translate these hormonal signals into coordinated behavioural and metabolic responses. The melanocortin system derived from POMC neurons is evolutionarily conserved across all mammals, including humans, nonhuman primates, and rodents, underscoring its fundamental importance in survival and energy regulation [21,22,23,24].

Structure And Function: Regulating Appetite And Metabolism

  • POMC Neurons as anorexigenic regulators. POMC neurons are anorexigenic (appetite-suppressing) neurons that decrease food intake and increase energy expenditure when activated. These neurons synthesize proopiomelanocortin, a large polypeptide precursor that undergoes complex post-translational processing to generate multiple bioactive peptides with distinct physiological functions. The primary bioactive products relevant to appetite regulation include alpha-melanocyte-stimulating hormone (α-MSH), a potent anorexigenic peptide, and beta-endorphin, an endogenous opioid with analgesic properties. The differential processing of POMC is tissue-specific and depends on the expression pattern of prohormone convertase enzymes [24,25,26].
  • POMC processing by prohormone convertases. The conversion of POMC into mature peptide hormones requires sequential enzymatic cleavages by two major endopeptidases: prohormone convertase 1/3 (PC1/3, also referred to as PC1) and prohormone convertase 2 (PC2). These enzymes belong to the subtilisin-like proprotein convertase family and are specifically localized to the secretory granules of neuroendocrine cells. PC1 and PC2 exhibit distinct cleavage specificities that determine the final peptide products generated from POMC. In hypothalamic POMC neurons, which typically express both PC1 and PC2, POMC is cleaved to produce adrenocorticotropic hormone (ACTH), which is further processed by PC2 into α-MSH and corticotropin-like intermediate peptide (CLIP). PC2 is particularly important for generating α-MSH, as demonstrated by studies showing that PC2 deficiency impairs α-MSH production. Following endopeptidase cleavage, carboxypeptidase E (CPE) removes C-terminal basic amino acid residues (lysine and arginine) from the cleaved peptides, and in some cases, α-MSH undergoes N-terminal acetylation, which does not affect its biological activity but distinguishes it from desacetyl-α-MSH. The critical role of these processing enzymes is underscored by findings that mutations in PC1/3 cause severe childhood obesity in humans, and defects in POMC processing lead to early-onset obesity phenotypes [25,26]. Importantly, leptin,the adipocyte-derived hormone that signals energy sufficiency stimulates the biosynthesis of both PC1 and PC2 in hypothalamic neurons, thereby enhancing the processing capacity for POMC and increasing the production of mature α-MSH. This represents an additional layer of regulation wherein nutritional status directly modulates the enzymatic machinery responsible for generating anorexigenic signals.
  • Leptin signalling in POMC neurons. POMC neurons express high levels of leptin receptors (LepRb), which are long-form receptors capable of activating intracellular signaling pathways. When leptin binds to LepRb on POMC neurons, it triggers activation of the Janus kinase 2 (JAK2)/signal transducer and activator of transcription 3 (STAT3) signaling pathway. Activated STAT3 translocates to the nucleus, where it binds to the POMC gene promoter and increases POMC gene transcription, thereby enhancing the production of POMC-derived peptides including α-MSH. This leptin-STAT3-POMC axis is essential for maintaining energy homeostasis, as mice with selective deletion of STAT3 in POMC neurons develop mild obesity and decreased POMC expression [28,29,30]. Leptin also activates the phosphatidylinositol 3-kinase (PI3K)/AKT signalling pathway in POMC neurons, which modulates neuronal excitability and firing frequency. Through these complementary signalling mechanisms, leptin simultaneously increases POMC gene expression and enhances the electrical activity of POMC neurons, thereby amplifying the anorexigenic output. However, chronic leptin stimulation paradoxically induces the expression of suppressor of cytokine signalling 3 (SOCS3), a negative feedback regulator that binds to LepRb and inhibits further leptin signalling. This negative feedback mechanism is thought to contribute to the development of leptin resistance in obesity, wherein POMC neurons become progressively less responsive to leptin despite elevated circulating leptin levels [30].
  • POMC projections and melanocortin signalling. POMC neurons project extensively throughout the hypothalamus and to extrahypothalamic brain regions involved in appetite control, energy expenditure, and autonomic regulation. The primary projection site is the paraventricular nucleus (PVN) of the hypothalamus, where α-MSH released from POMC axon terminals binds to melanocortin-4 receptors (MC4R) expressed on postsynaptic neurons. MC4R is a G-protein-coupled receptor that, upon α-MSH binding, primarily signals through the Gαs pathway to increase intracellular cyclic AMP (cAMP) levels, leading to decreased food intake and increased energy expenditure. MC4R also signals through Gαq/11-mediated pathways that increase intracellular calcium and modulate neuronal firing. Activation of MC4R neurons in the PVN is both necessary and sufficient for the appetite-suppressing effects of the melanocortin system [11,22,30,31]. In addition to the PVN, POMC neurons project to other hypothalamic nuclei including the dorsomedial hypothalamus (DMH), lateral hypothalamus (LH), and ventromedial hypothalamus (VMH), as well as to extrahypothalamic sites such as the amygdala, lateral septum, zona incerta, and brainstem nuclei including the nucleus tractus solitarii (NTS) and dorsal motor nucleus of the vagus (DMV). These widespread projections allow POMC neurons to influence not only feeding behaviour but also autonomic nervous system activity, cardiovascular function, glucose homeostasis, and stress responses. For example, MC4R activation in the brainstem and spinal cord increases sympathetic nervous system outflow and energy expenditure, while MC4R signalling in the PVN activates corticotropin-releasing hormone (CRH) neurons, linking the melanocortin system to stress axis regulation [30,32].
  • Functional effects of POMC neuron activation. Optogenetic or chemogenetic activation of POMC neurons rapidly suppresses food intake in mice, even in food-deprived animals, demonstrating the powerful anorexigenic capacity of this neuronal population. Conversely, selective ablation or chronic silencing of POMC neurons leads to hyperphagia (excessive eating) and obesity, underscoring their essential role in maintaining energy balance. The effects of POMC neuron activation on feeding behaviour are rapid, occurring within minutes of stimulation, and are mediated primarily through α-MSH release and MC4R activation in downstream target neurons. Importantly, POMC neurons also regulate systemic metabolic parameters beyond feeding: they modulate insulin sensitivity, glucose homeostasis, hepatic gluconeogenesis, and thermogenesis in brown adipose tissue. Recent studies have demonstrated that simultaneous activation of POMC neurons and inhibition of AgRP neurons (described below) produces additive effects on feeding suppression, revealing the precise bidirectional control of appetite through these reciprocal neuronal populations [23,31,33].

Key Neuronal Signals: AGRP/NPY Vs POMC

Within the arcuate nucleus, two functionally antagonistic neuronal populations exert opposing control over appetite and energy balance: the orexigenic (appetite-stimulating) AgRP/NPY neurons and the anorexigenic (appetite-suppressing) POMC neurons. These two neuronal populations are reciprocally regulated by peripheral metabolic signals and maintain a dynamic balance that determines feeding behaviour and metabolic state [24,34].

  • AgRP/NPY neurones: the hunger neurons. Agouti-related protein (AgRP) and neuropeptide Y (NPY) are co-expressed in a distinct population of neurons in the arcuate nucleus, often referred to simply as AgRP neurons. These neurons are potently orexigenic—their activation drives intense food-seeking behaviour and consumption, while their selective ablation in adult mice causes aphagia (cessation of eating) and eventual starvation. AgRP/NPY neurons are activated during energy deficit states such as fasting, when circulating levels of leptin and insulin decline and levels of the orexigenic hormone ghrelin rise. Conversely, these neurons are rapidly inhibited by the sensory detection of food—even before actual consumption begins—demonstrating their role as dynamic sensors of feeding opportunity rather than merely responding to nutritional repletion [24,34,35,36]. AgRP neurons synthesize and release three distinct signalling molecules that co-ordinately promote feeding: AgRP peptide, NPY, and the inhibitory neurotransmitter GABA (gamma-aminobutyric acid). Each of these molecules contributes to feeding behaviour over different timescales. NPY acts rapidly and is uniquely required for sustaining hunger over the timescale of a meal (tens of minutes after food discovery). When AgRP neurons are optogenetically pre-stimulated for several minutes and then turned off, the hunger drive persists for approximately 47 minutes, and this long-lasting hunger signal is entirely dependent on NPY, as mice lacking NPY do not exhibit prolonged feeding following AgRP neuron stimulation. AgRP peptide in contrast, modulates feeding behaviour over much longer timescales—days to weeks—by acting as an endogenous inverse agonist and competitive antagonist of melanocortin receptors (MC4R). AgRP suppresses the constitutive (baseline) activity of MC4R and simultaneously blocks the effects of α-MSH, thereby disinhibiting feeding circuits. The prolonged effects of AgRP peptide are thought to reflect its slow clearance from the brain and its ability to persistently antagonize melanocortin signalling. GABA released from AgRP neurons provides rapid synaptic inhibition of downstream neurons, including direct inhibition of POMC neurons within the arcuate nucleus and inhibition of anorexigenic neurons in the PVN and parabrachial nucleus (PBN) [12,34,36,37]. AgRP neurons project not only within the arcuate nucleus (where they directly inhibit neighbouring POMC neurons) but also extensively throughout the hypothalamus to the PVN, DMH, LH, bed nucleus of the stria terminalis (BNST), and to the PBN in the brainstem. These projections allow AgRP neurons to coordinate a comprehensive orexigenic response encompassing hunger, food-seeking motivation, reduced energy expenditure, and suppression of satiety signals. Stimulation of AgRP neuron projections to the PBN, for example, increases feeding during appetite-suppressing conditions induced by hormones such as amylin and cholecystokinin (CCK) or by gastric discomfort, demonstrating that AgRP neurons can override peripheral satiety signals to promote food intake during homeostatic need [12,34,37].
  • Reciprocal regulation between AgRP/NPY and POMC neurons. AgRP/NPY and POMC neurons are reciprocally regulated by the same peripheral hormones but in opposite directions, creating a push-pull system for appetite control. Leptin which signals energy abundance, activates POMC neurons (stimulating anorexigenic output) and simultaneously inhibits AgRP/NPY neurons (suppressing orexigenic signals). This dual action amplifies the appetite-suppressing effect of leptin. Conversely, ghrelin an orexigenic hormone secreted by the stomach during fasting, activates AgRP/NPY neurons and inhibits POMC neurons, thereby promoting hunger and food intake. This reciprocal hormonal regulation ensures that changes in nutritional status produce coordinated and robust changes in feeding behaviour [34,35,38,39]. Importantly, AgRP and POMC neurons also interact directly at the synaptic level. AgRP neurons send GABAergic (inhibitory) projections onto POMC neurons within the arcuate nucleus, thereby directly suppressing POMC neuron activity when hunger signals are high. This local inhibitory circuit creates a competitive interaction wherein activation of AgRP neurons not only promotes feeding through their own downstream targets but also actively silences the opposing POMC-mediated satiety signals. Recent studies using simultaneous optogenetic manipulation of both neuronal populations have demonstrated that food intake is regulated by the additive effect of AgRP neuron activation and POMC neuron inhibition, revealing that these two populations function as opposing arms of a single integrated appetite control system rather than as independent parallel pathways [33,34,37].
  • Neuronal activity dynamics during feeding. A striking feature of AgRP neurons is their rapid inhibition upon sensory detection of food, occurring within seconds of food presentation and well before actual consumption begins. This rapid silencing is mediated by sensory cues (sight, smell, and taste of food) and by learned associations between environmental contexts and food availability. Despite this rapid silencing, AgRP neuron stimulation generates a hunger signal that persists for tens of minutes, allowing feeding behaviour to continue even after the neurons themselves have ceased firing. This temporal dissociation between neuronal activity and behavioural output is mediated by the slow-acting neurotransmitter NPY, which sustains hunger during the interval between food discovery and consumption [36]. In contrast, POMC neurons exhibit different dynamics: they are progressively activated during feeding and in response to meal-related gut hormones such as cholecystokinin (CCK), peptide YY (PYY), and glucagon-like peptide-1 (GLP-1), providing a rising satiety signal that terminates the meal. The reciprocal dynamics of AgRP and POMC neurons with AgRP neurons silenced and POMC neurons activated during feeding create a neural state conducive to satiety and meal termination [23,34].
  • Downstream circuits and behavioural outputs. Both AgRP and POMC neurons engage extensive downstream neural circuits that translate their activity into specific behavioural and physiological outcomes. A critical convergence point is the PVN, where AgRP projections release NPY and GABA to promote feeding, while POMC projections release α-MSH to suppress feeding via MC4R activation. These opposing signals act on overlapping populations of PVN neurons expressing NPY receptors (Y1R and Y5R) and MC4R, creating a site of direct competition between orexigenic and anorexigenic drives [12,24,31,33,38]. Beyond the PVN, AgRP and POMC neurons also project to reward-related brain regions including the nucleus accumbens (NAcc), prefrontal cortex (PFC), and lateral hypothalamus, where they modulate the motivational and hedonic aspects of feeding. Activation of the subset of orexigenic neurons derived from embryonic POMC-expressing progenitors (which includes some AgRP neurons) engages extensive reward circuits involving the endogenous opioid system, as evidenced by the fact that their feeding-promoting effects are blocked by opioid receptor antagonists such as naloxone. This suggests that AgRP neurons not only drive homeostatic feeding (eating to meet energy needs) but also modulate food reward and the motivational drive to seek palatable foods [40].

In summary, the hypothalamic POMC pathway serves as a central integrator of metabolic status and appetite regulation, with POMC neurons functioning as key anorexigenic effectors that suppress feeding and increase energy expenditure in response to signals of energy sufficiency. These neurons act in dynamic opposition to AgRP/NPY neurons, which drive hunger and feeding during energy deficit. The reciprocal regulation of these two neuronal populations by peripheral hormones (particularly leptin and ghrelin) and their direct synaptic interactions create a bidirectional control system that precisely regulates energy balance. Disruptions in this system, whether through genetic mutations affecting leptin, POMC, or melanocortin receptors, or through acquired leptin resistance in obesity, result in profound disturbances of appetite control and metabolic homeostasis, underscoring the critical importance of the hypothalamic melanocortin pathway in human health and disease.

Clinical And Practical Implications

Understanding Obesity Beyond Willpower

The conventional narrative surrounding obesity has long positioned weight gain as a matter of personal responsibility—a simple equation of calories consumed versus calories expended, where failure to maintain balance reflects inadequate discipline or willpower. However, emerging evidence from genetic, hormonal, and metabolic research fundamentally challenges this reductionist view, revealing obesity as a complex neurometabolic disease driven by intricate biological mechanisms that extend far beyond volitional control [41,42].

Monogenic forms of obesity, rare genetic conditions including leptin deficiency, proopiomelanocortin (POMC) deficiency, and melanocortin 4 receptor (MC4R) mutations provide compelling evidence that disruptions in specific hormonal signalling pathways can drive dramatic fat accumulation even when caloric intake remains controlled. These genetic disorders disrupt the hypothalamic POMC pathway, a critical brain circuit that regulates appetite and metabolism, essentially reprogramming the body to store energy as fat regardless of food consumption. Studies of individuals with these mutations demonstrate that weight gain occurs not through increased eating, but through fundamental alterations in how the body partitions energy between storage and expenditure [2,43].

The genetic architecture of common obesity further supports this paradigm shift. Genome wide association studies have identified hundreds of genetic variants associated with body mass index and obesity risk, with research suggesting that genetic factors may influence up to 75% of obesity cases. Notably, common variants in the fat mass and obesity-associated FTO gene and near the MC4R gene represent the strongest genetic contributors to polygenic obesity in the general population. These genetic variants affect metabolic processes including appetite regulation, satiety signalling, fat storage capacity, and energy expenditure, biological functions that operate largely outside conscious control [43,44].

The “thrifty genotype” hypothesis offers an evolutionary framework for understanding this genetic predisposition. This theory posits that genes promoting efficient energy storage conferred survival advantages during periods of food scarcity throughout human evolution, but become maladaptive in modern environments characterized by constant food availability. While debated, this hypothesis underscores that obesity vulnerability may reflect ancestral adaptations rather than contemporary moral failings [45,46].

Beyond genetics, obesity emerges as a condition of disrupted hormonal communication. The adipocyte derived hormone leptin, which signals energy stores to the hypothalamus and normally suppresses appetite and promotes satiety, becomes ineffective in most individuals with obesity through a phenomenon termed “leptin resistance”. Despite elevated circulating leptin levels proportional to increased fat mass, the brain fails to respond appropriately to leptin’s satiety signals, resulting in persistent hunger and continued weight gain. This resistance operates at multiple levels, including impaired leptin transport across the blood-brain barrier and downstream disruption of intracellular signalling cascades. Similarly, alterations in ghrelin (the “hunger hormone”), peptide YY, and other gut-derived hormones further dysregulate the delicate homeostatic balance governing energy intake and expenditure [47,48,49].

Critically, these hormonal and genetic factors intersect with psychosocial and environmental influences to create individual-specific obesity phenotypes. Metabolically healthy obesity, characterized by preserved insulin sensitivity despite excess adiposity, versus metabolically unhealthy obesity, marked by insulin resistance and cardiometabolic complications, demonstrates that obesity represents a heterogeneous condition with distinct pathophysiological underpinnings. This heterogeneity reflects variations in adipose tissue expandability, fat distribution patterns, inflammatory status, and mitochondrial function, biological determinants that cannot be addressed through willpower alone [50,51].

Recognizing obesity as a biological disease rather than a behavioural failure has profound clinical implications. This reconceptualization combats weight stigma, which itself contributes to psychological distress and paradoxically may worsen metabolic outcomes. It validates patient experiences of struggling with weight despite earnest efforts and opens therapeutic avenues targeting underlying pathophysiology rather than simply prescribing caloric restriction. Healthcare providers equipped with this understanding can approach obesity management with greater empathy, precision, and ultimately, effectiveness [50,52,53].

Recognizing The Biochemical Drivers

At the molecular level, obesity pathogenesis centres on the hormone insulin and its dominant control over energy partitioning—the biological process determining whether consumed calories are stored as fat or burned for energy. The Carbohydrate-Insulin Model (CIM) of obesity proposes that chronic consumption of high glycemic load carbohydrates stimulates excessive insulin secretion, which in turn promotes preferential energy storage in adipose tissue, leaving fewer calories available for utilization by other tissues and consequently driving compensatory increases in hunger and food intake. According to this model, obesity results not from overeating per se, but from hormonal signals that favour fat accumulation; overeating becomes a consequence rather than the cause of weight gain [42,54,55,56].

Insulin exerts profound anabolic effects on adipocytes by stimulating glucose uptake, promoting triglyceride synthesis, suppressing lipolysis (fat breakdown), and inhibiting the release of free fatty acids into circulation. These actions collectively favour lipid storage within adipose tissue. Genetic and pharmacological evidence supports insulin’s causal role in fat accumulation: genetic variants associated with insulin hypersecretion predict greater weight gain over time, while interventions that reduce insulin secretion promote weight loss. Conversely, insulin administration—whether for therapeutic purposes in diabetes or experimentally in animal models consistently causes weight gain [42,54,56].

Emerging evidence identifies primary insulin hypersecretion as a potential initiator of obesity and metabolic dysfunction. In this paradigm, pancreatic beta cells secrete excessive insulin in response to metabolic signals including elevated free fatty acids released from expanding adipose tissue mass, creating a self-perpetuating cycle. The hyperinsulinemia drives further fat storage through direct lipogenic effects while simultaneously inducing insulin resistance through receptor downregulation and impaired intracellular signalling a protective mechanism preventing hypoglycemia but exacerbating metabolic dysfunction. Importantly, insulin resistance may develop as an adaptive homeostatic response to chronic hyperinsulinemia rather than representing a primary defect [42,54,56].

The biology of adipose tissue expansion further illuminates obesity’s biochemical basis. Adipose tissue can expand through adipocyte hypertrophy (increased cell size) or hyperplasia (increased cell number). Healthy adipose tissue expansion through hyperplasia, characterized by recruitment and differentiation of adipocyte precursor cells, maintains metabolic function and insulin sensitivity. In contrast, pathological expansion dominated by hypertrophy, where individual adipocytes become excessively enlarged leads to adipocyte dysfunction, hypoxia, inflammation, and ectopic lipid deposition in liver and skeletal muscle. This ectopic fat accumulation drives insulin resistance in these metabolically critical tissues through multiple mechanisms including accumulation of toxic lipid metabolites (diacylglycerol, ceramides) that interfere with insulin signalling [57,58,59,60].

The capacity for healthy adipose tissue expansion varies substantially between individuals due to genetic, epigenetic, and developmental factors. Individuals with limited subcutaneous adipose tissue expandability, analogous to lipodystrophy syndromes where subcutaneous fat stores are congenitally absent developing metabolic complications at lower body weights than those with greater storage capacity. This concept of “personal fat threshold” suggests that obesity-related metabolic disease occurs when an individual exceeds their genetically determined capacity to safely store excess energy in subcutaneous adipose tissue, necessitating pathological overflow into visceral depots and ectopic sites [58,59,60].

Adipose tissue also functions as an active endocrine organ secreting numerous hormones and cytokines collectively termed adipokines. Beyond leptin, adipocytes produce adiponectin (which enhances insulin sensitivity), tumor necrosis factor-alpha and interleukin-6 (pro-inflammatory cytokines that promote insulin resistance), and numerous other signalling molecules that modulate whole-body metabolism, inflammation, and cardiovascular function. In obesity, particularly when characterized by visceral adiposity and adipocyte hypertrophy, adipokine secretion patterns shift toward a pro-inflammatory, insulin resistant profile. Infiltration of adipose tissue by macrophages and other immune cells further amplifies inflammatory signalling, creating a state of chronic low-grade inflammation that links obesity to its metabolic and cardiovascular complications [50,58,59,60,61,62].

Genetic variants affecting adipocyte biology provide additional mechanistic insights. Polymorphisms in peroxisome proliferator-activated receptor gamma (PPARγ), a master transcriptional regulator of adipogenesis, influence both obesity susceptibility and insulin sensitivity. The common Pro12Ala variant in PPARγ, associated with reduced adipogenic capacity, paradoxically decreases obesity risk while potentially impairing the metabolically protective expansion of subcutaneous fat stores. Similarly, variants in genes encoding proteins involved in triglyceride synthesis (diacylglycerol acyltransferase), lipolysis (hormone-sensitive lipase, perilipin), and adipocyte differentiation collectively shape individual responses to positive energy balance [50,59].

The recognition that obesity arises from complex interactions between genetic predisposition, hormonal regulation, adipose tissue biology, and inflammatory processes—rather than simply reflecting excessive caloric intake fundamentally transforms clinical approaches to obesity management. This biochemical understanding provides the scientific foundation for precision medicine strategies that target specific pathophysiological mechanisms in individual patients [50,63].

Conclusion

Rare monogenic obesity syndromes and polygenic risk architectures reveal that genetics significantly dictate an individual’s susceptibility to fat gain, influencing appetite regulation, satiety signalling, adipocyte biology, and metabolic partitioning. Hormonal factors, particularly leptin and adiponectin, further modulate energy storage and expenditure, yet it is insulin that emerges as the central “authority” in fat regulation. Insulin not only directs the uptake and long-term storage of energy substrates as fat but also powerfully suppresses fat breakdown, chronic hyperinsulinemia, whether genetically or nutritionally riven, locks the body into a fat storing mode, independent of simple caloric excess.

Disruptions in the hypothalamic POMC-melanocortin pathway, leptin signalling, and adipokine secretion all converge on the downstream effect of sustained high insulin, which reallocates calories toward storage rather than oxidation. These insights are reinforced by both clinical genetic evidence (e.g., MC4R and FTO mutations) and intervention studies demonstrating that modifying insulin dynamics (through diet, medication, or bariatric interventions) can have profound impacts on fat loss and metabolic health even when calorie intake is controlled.

For metabolic health prevention, the take home message is that effective strategies must go beyond restricting calories alone. Precision approaches are needed: understanding an individual’s genetic risk, targeting hormonal drivers such as insulin, designing personalized dietary and activity interventions that lower glycemic and insulinemic loads, and addressing the psychosocial and behavioural environment. Recognizing obesity and metabolic disease as conditions rooted in biology, rather than blame, empowers clinicians and patients to pursue evidence-based, mechanism driven prevention and management for sustainable health outcomes.

References

  1. Wons MK, Goody JJ. Complete IT Framework for Success. Trafford Publishing; 2002.
  2. The Real Cause of Fat Gain: Genetics, Hormones, and Insulin | The Metabolic Classroom with Dr. Ben Bikman [Internet]. Acast.com. 2025 [cited 2025 Oct 28]. Available from: https://shows.acast.com/the-metabolic-classroom/episodes/the-real-cause-of-fat-gain-genetics-hormones-and-insulin
  3. Dahlman I, Mikael Rydén, Brodin D, Harald Grallert, Strawbridge RJ. Numerous Genes in Loci Associated With Body Fat Distribution Are Linked to Adipose Function. Diabetes. 2016 Jan 13;65(2):433–7.
  4. Funcke JB, von Schnurbein J, Lennerz B, Lahr G, Debatin KM, Fischer-Posovszky P, et al. Monogenic forms of childhood obesity due to mutations in the leptin gene. Molecular and Cellular Pediatrics [Internet]. 2014 Sep 4;1(1). Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4644131/
  5. Salum KCR, Rolando J de M, Zembrzuski VM, Carneiro JRI, Mello CB, Maya-Monteiro CM, et al. When Leptin Is Not There: A Review of What Nonsyndromic Monogenic Obesity Cases Tell Us and the Benefits of Exogenous Leptin. Frontiers in Endocrinology. 2021 Aug 24;12.
  6. van, Lotte Kleinendorst, Patric, van, Visser JA, Haelst van, et al. Obesity and Hyperphagia With Increased Defective ACTH: A Novel POMC The Journal of Clinical Endocrinology & Metabolism [Internet]. 2022 Jun 23 [cited 2024 Feb 22];107(9):e3699–704. Available from: https://academic.oup.com/jcem/article/107/9/e3699/6614243?login=false
  7. Challis BG, Coll AP, Seow G, Pinnock SB, Dickson SL, Thresher R, et al. Mice lacking pro-opiomelanocortin are sensitive to high-fat feeding but respond normally to the acute anorectic effects of peptide-YY . 2004 Mar 30;101(13):4695–700. 3-36
  8. Welcome To Zscaler Directory Authentication [Internet]. Oup.com. 2025 [cited 2025 Oct 28]. Available from: https://academic.oup.com/jcem/article-abstract/93/11/4494/2627319?redirectedFrom=fulltext&login=false
  9. Proopiomelanocortin deficiency: MedlinePlus Genetics [Internet]. medlineplus.gov. Available from: https://medlineplus.gov/genetics/condition/proopiomelanocortin-deficiency
  10. Vaisse C, Clement K, Durand E, Hercberg S, Guy-Grand B, Froguel P. Melanocortin-4 receptor mutations are a frequent and heterogeneous cause of morbid obesity. The Journal of clinical investigation [Internet]. 2000;106(2):253–62. Available from: https://www.ncbi.nlm.nih.gov/pubmed/10903341
  11. Metzger PJ, Zhang A, Carlson BA, Sun H, Cui Z, Li Y, et al. A human obesity-associated MC4R mutation with defective Gq/11α signaling leads to hyperphagia in mice. The Journal of Clinical Investigation [Internet]. 2024 Feb 15 [cited 2024 May 2];134(4). Available from: https://www.jci.org/articles/view/165418#:~:text=MC4R mutations are the most
  12. Baldini G, Phelan KD. The melanocortin pathway and control of appetite-progress and therapeutic implications. Journal of Endocrinology [Internet]. 2019 Apr;241(1):R1–33. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6500576/
  13. Archer E, Pavela G, McDonald S, Lavie CJ, Hill JO. Cell-Specific “Competition for Calories” Drives Asymmetric Nutrient-Energy Partitioning, Obesity, and Metabolic Diseases in Human and Non-human Animals. Frontiers in Physiology. 2018 Aug 10;9.
  14. Salum KCR, Rolando J de M, Zembrzuski VM, Carneiro JRI, Mello CB, Maya-Monteiro CM, et al. When Leptin Is Not There: A Review of What Nonsyndromic Monogenic Obesity Cases Tell Us and the Benefits of Exogenous Leptin. Frontiers in Endocrinology. 2021 Aug 24;12.
  15. Funcke JB, von Schnurbein J, Lennerz B, Lahr G, Debatin KM, Fischer-Posovszky P, et al. Monogenic forms of childhood obesity due to mutations in the leptin gene. Molecular and Cellular Pediatrics [Internet]. 2014 Sep 4;1(1). Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4644131/
  16. Martin Carli JF, LeDuc CA, Zhang Y, Stratigopoulos G, Leibel RL. FTO mediates cell-autonomous effects on adipogenesis and adipocyte lipid content by regulating gene expression via 6mA DNA modifications1. Journal of Lipid Research [Internet]. 2018 Aug 1;59(8):1446–60. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6071765/
  17. Lan N, Lu Y, Zhang Y, Pu S, Xi H, Nie X, et al. FTO – A Common Genetic Basis for Obesity and Cancer. Frontiers in Genetics. 2020 Nov 16;11.
  18. Krycer JR, Quek LE, Francis D, Zadoorian A, Weiss FC, Cooke KC, et al. Insulin signaling requires glucose to promote lipid anabolism in adipocytes. Journal of Biological Chemistry [Internet]. 2020 Sep 18;295(38):13250–66. Available from: https://www.sciencedirect.com/science/article/pii/S0021925817500411
  19. Rahman S. Role of Insulin in Health and Disease: an Update. International Journal of Molecular Sciences [Internet]. 2021 Jun 15;22(12):6403. Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC8232639/
  20. Carpentier AC. 100th anniversary of the discovery of insulin perspective: insulin and adipose tissue fatty acid metabolism. American Journal of Physiology Endocrinology and Metabolism [Internet]. 2021 Apr 1;320(4):E653–70. Available from: https://pubmed.ncbi.nlm.nih.gov/33522398/
  21. Zheng H, Patterson LM, Rhodes CJ, Louis GW, Skibicka KP, Grill HJ, et al. A potential role for hypothalamomedullary POMC projections in leptin-induced suppression of food intake. American Journal of Physiology-regulatory Integrative and Comparative Physiology. 2010 Mar 1;298(3):R720–8.
  22. Baldini G, Phelan KD. The melanocortin pathway and control of appetite-progress and therapeutic implications. Journal of Endocrinology [Internet]. 2019 Apr;241(1):R1–33. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6500576/
  23. Jais A, Brüning JC. Arcuate Nucleus-Dependent Regulation of Metabolism—Pathways to Obesity and Diabetes Mellitus. Endocrine Reviews. 2021 Sep 7;43(2).
  24. Sohn JW. Network of hypothalamic neurons that control appetite. BMB Reports [Internet]. 2015 Apr 30;48(4):229–33. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4436859/
  25. Marcinkiewicz M, Day R, Seidah NG, M Chrétien. Ontogeny of the prohormone convertases PC1 and PC2 in the mouse hypophysis and their colocalization with corticotropin and alpha-melanotropin. Proceedings of the National Academy of Sciences [Internet]. 1993 Jun 1 [cited 2025 Oct 28];90(11):4922–6. Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC46625/
  26. Benjannet S, Rondeau N, Day R, Chrétien M, Seidah NG. PC1 and PC2 are proprotein convertases capable of cleaving proopiomelanocortin at distinct pairs of basic residues. Proceedings of the National Academy of Sciences. 1991 May;88(9):3564–8.
  27. Ernst MB, Wunderlich CM, Hess S, Paehler M, Mesaros A, Koralov SB, et al. Enhanced Stat3 Activation in POMC Neurons Provokes Negative Feedback Inhibition of Leptin and InsulinSignaling in Obesity. Journal of Neuroscience. 2009 Sep 16;29(37):11582–93.
  28. Gamber KM, Huo L, Ha S, Hairston JE, Greeley S, Bjørbæk C. Over-Expression of Leptin Receptors in Hypothalamic POMC Neurons Increases Susceptibility to Diet-Induced Obesity. PLoS ONE [Internet]. 2012 Jan 20 [cited 2020 Mar 30];7(1). Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3262822/#pone.0030485-Munzberg1
  29. Balthasar N, Coppari R, McMinn J, Liu SM, Lee CE, Tang V, et al. Leptin Receptor Signaling in POMC Neurons Is Required for Normal Body Weight Homeostasis. Neuron [Internet]. 2004 Jun;42(6):983–91. Available from: https://www.cell.com/neuron/fulltext/S0896-6273(04)00354-X
  30. Lu X, Barsh GS, Akil H, Watson SJ. Interaction between α-Melanocyte-Stimulating Hormone and Corticotropin-Releasing Hormone in the Regulation of Feeding and Hypothalamo-Pituitary-Adrenal Responses. 2003 Aug 27;23(21):7863–72.
  31. Ghamari-Langroudi M, Srisai D, Cone RD. Multinodal regulation of the arcuate/paraventricular nucleus circuit by leptin. Proceedings of the National Academy of Sciences. 2010 Dec 15;108(1):355–60.
  32. Copperi F, Kim JD, Diano S. Role of the Melanocortin System in the Central Regulation of Cardiovascular Functions. Frontiers in Physiology. 2021 Aug 25;12.
  33. Alain, Almudena Del Río-Martín, Radermacher J, Chen W, Steuernagel L, Bauder CA, et al. Reciprocal activity of AgRP and POMC neurons governs coordinated control of feeding and metabolism. Nature Metabolism [Internet]. 2024 Feb 20; Available from: https://www.nature.com/articles/s42255-024-00987-z#:~:text=Agouti-related peptide (AgRP)-
  34. Vohra MS, Benchoula K, Serpell CJ, Hwa WE. AgRP/NPY and POMC neurons in the arcuate nucleus and their potential role in treatment of obesity. European Journal of Pharmacology [Internet]. 2022 Jan 15;915:174611. Available from: https://www.sciencedirect.com/science/article/abs/pii/S0014299921007676
  35. So WL, Hu J, Jeffs L, Dempsey H, Lockie SH, Zigman JM, et al. Ghrelin signalling in AgRP neurons links metabolic state to the sensory regulation of AgRP neural activity. Molecular Metabolism [Internet]. 2023 Dec 1 [cited 2023 Dec 4];78:101826. Available from: https://pubmed.ncbi.nlm.nih.gov/37898450/
  36. Chen Y, Essner RA, Kosar S, Miller OH, Lin YC, Mesgarzadeh S, et al. Sustained NPY signaling enables AgRP neurons to drive feeding. eLife. 2019 Apr 29;8.
  37. Essner RA, Smith AG, Jamnik AA, Ryba AR, Trutner ZD, Carter ME. AgRP Neurons Can Increase Food Intake during Conditions of Appetite Suppression and Inhibit Anorexigenic Parabrachial Neurons. The Journal of Neuroscience. 2017 Aug 7;37(36):8678–87.
  38. Chen HS, Trumbauer ME, Chen A, Weingarth DT, Adams JR, Frazier EG, et al. Orexigenic Action of Peripheral Ghrelin Is Mediated by Neuropeptide Y and Agouti-Related Protein. 2004 Feb 12;145(6):2607–12. Available from: https://academic.oup.com/endo/article/145/6/2607/2878006?login=false
  39. Munzberg H, Jobst EE, Bates SH, Jones J, Villanueva E, Leshan R, et al. Appropriate Inhibition of Orexigenic Hypothalamic Arcuate Nucleus Neurons Independently of Leptin Receptor/STAT3 Signaling. Journal of Neuroscience. 2007 Jan 3;27(1):69–74.
  40. Wei Q, Krolewski DM, Moore S, Kumar V, Li F, Martin B, et al. Uneven balance of power between hypothalamic peptidergic neurons in the control of feeding. Proceedings of the National Academy of Sciences. 2018 Sep 17;115(40):E9489–98.
  41. Masood B, Moorthy M. Causes of obesity: a review. Clinical Medicine. 2023 Jul 1;23(4):284–91.
  42. Ludwig DS, Ebbeling CB. The Carbohydrate-Insulin Model of Obesity. JAMA Internal Medicine. 2018 Aug 1;178(8):1098.
  43. Loos RJF, Yeo GSH. The genetics of obesity: from discovery to biology. Nature Reviews Genetics. 2021 Sep 23;23(23):1–14.
  44. Yang Y, Gao X, Tao X, Gao Q, Zhang Y, Yang J. Combined effect of FTO and MC4R gene polymorphisms on obesity in children and adolescents in Northwest China: a case-control study. PubMed. 2019 Jan 1;28(1):177–82.
  45. OʼRourke RW. Metabolic Thrift and the Genetic Basis of Human Obesity. Annals of Surgery. 2014 Apr;259(4):642–8.
  46. Speakman JR. Thrifty genes for obesity, an attractive but flawed idea, and an alternative perspective: the “drifty gene” hypothesis. International Journal of Obesity. 2008 Oct 14;32(11):1611–7.
  47. Yeung AY, Tadi P. Physiology, obesity neurohormonal appetite and satiety control [Internet]. PubMed. Treasure Island (FL): StatPearls Publishing; 2023. Available from: https://www.ncbi.nlm.nih.gov/books/NBK555906/
  48. Klok MD, Jakobsdottir S, Drent ML. The role of leptin and ghrelin in the regulation of food intake and body weight in humans: a review. Obesity reviews : an official journal of the International Association for the Study of Obesity [Internet]. 2007;8(1):21–34. Available from: https://onlinelibrary.wiley.com/doi/10.1111/j.1467-789X.2006.00270.x
  49. Obradovic M, Sudar-Milovanovic E, Soskic S, Essack M, Arya S, Stewart AJ, et al. Leptin and obesity: Role and clinical Implication. Frontiers in Endocrinology [Internet]. 2021;12(12). Available from: https://www.frontiersin.org/articles/10.3389/fendo.2021.585887/full
  50. Lustig RH, Collier D, Kassotis C, Roepke TA, Kim MJ, Blanc E, et al. Obesity I: Overview and molecular and biochemical mechanisms. Biochemical Pharmacology. 2022 May;199:115012.
  51. Choe SS, Huh JY, Hwang IJ, Kim JI, Kim JB. Adipose Tissue Remodeling: Its Role in Energy Metabolism and Metabolic Disorders. Frontiers in Endocrinology [Internet]. 2016 Apr 13;7. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4829583/
  52. Maria Daniela HA, Acosta A. Precision Medicine and Obesity. Gastroenterology clinics of North America [Internet]. 2021 Mar 1;50(1):127–39. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7863578/
  53. Cifuentes L, Wissam Ghusn, Feris F, Campos A, Sacoto D, De A, et al. Phenotype tailored lifestyle intervention on weight loss and cardiometabolic risk factors in adults with obesity: a single-centre, non-randomised, proof-of-concept study. EClinicalMedicine. 2023 Apr 1;58:101923–3.
  54. Mittendorfer B, Johnson JD, Solinas G, Jansson PA. Insulin Hypersecretion as Promoter of Body Fat Gain and Hyperglycemia. Diabetes [Internet]. 2024 May 20;73(6):837–43. Available from: https://diabetesjournals.org/diabetes/article/73/6/837/154590/Insulin-Hypersecretion-as-Promoter-of-Body-Fat
  55. Fryk E, Olausson J, Mossberg K, Strindberg L, Schmelz M, Brogren H, et al. Hyperinsulinemia and insulin resistance in the obese may develop as part of a homeostatic response to elevated free fatty acids: A mechanistic case-control and a population-based cohort study. EBioMedicine. 2021 Mar;65:103264.
  56. Hall KD, Farooqi IS, Friedman JM, Klein S, Loos RJF, Mangelsdorf DJ, et al. The energy balance model of obesity: beyond calories in, calories out. The American Journal of Clinical Nutrition. 2022 Feb 4;115(5).
  57. Blüher M. Metabolically Healthy Obesity. Endocrine Reviews [Internet]. 2020 Mar 4;41(3):405–20. Available from: https://academic.oup.com/edrv/article/41/3/bnaa004/5780090
  58. Ye J. Mechanisms of insulin resistance in obesity. Frontiers of Medicine [Internet]. 2013 Mar;7(1):14–24. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3936017/
  59. McPherson R. Genetic contributors to obesity. Canadian Journal of Cardiology [Internet]. 2007 Aug;23(1):23A27A. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2787002/pdf/cjc23023a.pdf
  60. Choe SS, Huh JY, Hwang IJ, Kim JI, Kim JB. Adipose Tissue Remodeling: Its Role in Energy Metabolism and Metabolic Disorders. Frontiers in Endocrinology [Internet]. 2016 Apr 13;7. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4829583/
  61. Attie AD, Scherer PE. Adipocyte metabolism and obesity. Journal of Lipid Research. 2009;50:S395–9.
  62. Rosen ED, Spiegelman BM. Adipocytes as regulators of energy balance and glucose homeostasis. Nature [Internet]. 2006 Dec;444(7121):847–53. Available from: https://www.nature.com/articles/nature05483
  63. Maria Daniela HA, Acosta A. Precision Medicine and Obesity. Gastroenterology clinics of North America [Internet]. 2021 Mar 1;50(1):127–39. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7863578/